Arrhythmias in Post-Myocardial Infarction Patients

NCT03231826 | Completed

• 1 other identifier: R17023
• Study Type: observational
• Target: 445
• Locations: 1 country
• Sites: 1

Brief Summary

Patients are screened for significant arrhythmias and other possibly significant ECG-patterns directly after discharge and two weeks after myocardial infarction using wearable devices. The home monitoring data will be linked with extensive data from electronic health records collected before, during hospital stay and after discharge. The purpose of the study is to clarify whether home monitoring of continuous ECG-signals can be used to predict and prevent serious adverse events after myocardial infarction.

Conditions

Myocardial Infarction; Coronary Artery Disease; Arrythmia; ECG Electrical Alternans; Atrioventricular Block; Atrial Fibrillation; Atrial Flutter; Ventricular Tachycardia; Ventricular Fibrillation; Ventricular Arrythmia

Keywords

Home monitoring; ECG; Myocardial Infarction; Arrythmia

Outcome Measures

Primary Outcomes (1)

• Cardiovascular mortality

  Mortality due to heart failure, complication of myocardial infarction, recurrent myocardial infarction, stroke or probable cardiac arrhythmia

  One month and one year and five after myocardial infarction

Secondary Outcomes (8)

• Incident asymptomatic atrial fibrillation

  Within two weeks after myocardial infarction

• Incident ventricular arrhythmias

  Within two weeks after myocardial infarction

• Incident bradyarrhytmias

  Within two weeks after myocardial infarction

• Rehospitalization

  One month and one year and five after myocardial infarction

• Rehospitalization (CVD)

  One month and one year and five after myocardial infarction

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patients treated at the study center (Tays Heart Hospital) between June 2017 and June 2019 fulfilling the eligibility criteria are invited to participate.

Sponsors & Collaborators

• Tampere University: lead
• Tays Heart Hospital: collaborator
• GE Healthcare Finland Ltd: collaborator
• Fimlab Ltd: collaborator
• VTT Technical Research Centre of Finland: collaborator
• Bittium Ltd: collaborator
• Tekes - Finnish Funding Agency for Innovation: collaborator
• Politecnico Milano: collaborator

Study Sites (1)

Tays Heart Hospital

Tampere, Pirkanmaa, 33540, Finland

Location

Related Links

• Cohort description for MADDEC consortia study plan

Biospecimen

Retention: SAMPLES WITHOUT DNA

Recording of continuous ECG-signals

MeSH Terms

Conditions

Myocardial Infarction; Coronary Artery Disease; Arrhythmias, Cardiac; Atrioventricular Block; Atrial Fibrillation; Atrial Flutter; Tachycardia, Ventricular; Ventricular Fibrillation

Condition Hierarchy (Ancestors)

Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Infarction; Ischemia; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Necrosis; Coronary Disease; Arteriosclerosis; Arterial Occlusive Diseases; Heart Block; Cardiac Conduction System Disease; Tachycardia

Study Officials

• Jussi A Hernesniemi, MD PhD

  Tays Heart Hospital and Tampere University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: July 24, 2017
• First Posted: July 27, 2017
• Study Start: June 22, 2017
• Primary Completion: February 28, 2019
• Study Completion: February 28, 2019
• Last Updated: August 12, 2025

Record last verified: 2019-04

Locations

FI (1)